Newborn screening
Newborn screening tests include :
- umbilical cord blood congenital syphilis screening (compulsory)
- congenital cataract screening - by equipping the red reflex in the pupil with an ophthalmoscope (compulsory since 2005
- congenital deafness screening - hearing examination using the method of transiently evoked otoacoustic emissions (compulsory from 2012)
- neonatal laboratory screening from blood taken from the heel :
- since 2022, screening for spinal muscular atrophy (SMA) and severe combined immunodeficiency disease (SCID) has been newly recommended - so far it is a pilot project, the examination is voluntary
- developmental dysplasia screening of the hip joint - examination of the hips by an orthopedist
- examination of congenital critical heart defects using pulse oximetry - comparison of SpO 2 on the right upper limb and lower limbs (optional)
- ultrasonographic examination of the kidneys (optional) .
In the narrower sense of the word, neonatal screening means neonatal laboratory screening .
Screening = systematic targeted search for a certain disease before its clinical manifestation in an effort to prevent its possible consequences in time
- according to the selected population in which the disorder is sought, we distinguish between nationwide screening (eg neonatal screening) and selective (in at-risk populations
- conditions for the introduction of nationwide screening:
- the sought-after disorder is clinically diagnosable only at a time when irreversible damage to the endangered system has already occurred, or without its early determination, the life of the carrier of the disorder may be immediately endangered
- the disorder has a sufficient incidence in the population
- effective treatment is available
- there is a screening test with high sensitivity and sufficient specificity
- the test is reasonably cheap (favorable cost / benefit ratio)[1].
Newborn laboratory screening[edit | edit source]
All neonates born in the Czech Republic are subjected to neonatal laboratory screening (NLS) of congenital or hereditary diseases listed below by the method of taking a so-called dry drop of blood on a neonatal screening card between 48 and 72 hours of age. The goal of neonatal screening is rapid diagnosis and early treatment of newborns with these diseases.
- hyperphenylalaninemia and phenylketonuria ;
- metoda: tandemová hmotnostní spektrometrie;
- congenital hypothyroidism ;
- method: determination of thyroid stimulating hormone (TSH) by fluoroimmunoassay (FIA;
- congenital adrenal hyperplasia;
- method: determination of 17alpha-OH-progesterone by immunoassay methods;;
- cystic fibrosis ;
- method: determination of immunoreactive trypsinogen (IRT) level by immunoassay method
- selected inherited metabolic disorders:
- method: tandem mass spectrometry
- spinal muscular atrophy and severe combined immunodeficiency (optional);
- method: quantitative real-time polymerase chain reactions (QRT-PCR).
Methodology for collecting a dry drop of blood for the screening card[edit | edit source]
- well washed, perfused skin on the inner or outer edge of the newborn's heel is cleaned with alcohol and allowed to dry
- a small incision is made to a depth of max. 2 mm with a sterile spear by hand or lancet (special automatic device designed for this purpose
- the first drop of blood is wiped off with a dry sterile swab
- after creating a sufficiently large additional drop, the filter paper of the screening card is gently applied so that the blood is sucked up and completely fills the pre-printed target and the filter paper is visibly soaked on both sides.
- the heel must not be squeezed or squeezed to prevent the admixture of tissue fluid
- the target must be soaked from one drop at a time, the drops must not be layered into one target
- it is necessary to soak up all the targets on the neonatal screening card with blood
- we never touch the filter paper and it is necessary to avoid contact of blood drops with any object,
- after collection, let the blood dry in the horizontal position of the card for at least 3 hours at room temperature (preferably in a special card drying rack)
- after the blood has dried, the drops are covered with a cover paper, which is part of the card
Screening for hyperphenylalaninemia and phenylketonuria[edit | edit source]
- in the Czech Republic has been carried out since 1975, incidence according to NLS results (2010-2016) about 1: 5500[2]
- hyperphenylalaninemia (HPA) = a disorder of phenylalanine metabolism in which it pathologically accumulates in the blood and other body fluids → hyperphenylalaninemia damages the CNS - affects the mental development of the child and leads to severe oligophrenia
- the most severe form: phenylketonuria (PKU) - incidence in the Czech Republic 1:10 000 live births
- in 97% the cause is a deficiency of the enzyme phenylalanine hydroxylase
- in1-3% the cause is tetrahydrobiopterin deficiency
- the most severe form: phenylketonuria (PKU) - incidence in the Czech Republic 1:10 000 live births
- treatment ( elimination diet ) should be started within 21 days at the latest
- screening : tandem mass spectrometry method (since 1.10.2009)
- collection of dry blood drops from the heel of the newborn is performed only 3-4. the day of life on which the child receives the dairy diet (so that the phenylalanine level is high enough
- phenylalanine is present in approximately 5% of breast milk protein
- Criteria for the diagnosis of classical phenylketonuria
- phenylalanine level above 20 mg / dl (above 1.2 mmol / l
- normal or decreased tyrosine levels
- the presence of abnormal metabolites in the urine (phenylpyruvic acid),
- normal concentration of tetrahydrobiopterin, a phenylalanine hydroxylation cofactor to tyrosine
Screening for congenital hypothyroidism[edit | edit source]
- in the Czech Republic has been carried out since 1985, incidence in the Czech Republic according to NLS: about 1: 3000 live newborns
- congenital hypothyroidism (CH) - a lack of thyroid hormones in children leads to impaired brain development with a subsequent irreversible mental defect of varying degrees. Clinical symptoms appear late (only when the CNS is irreversibly affected)
- it arises on the basis of thyroid dysgenesis (agenesis, hypoplasia, ectopy) or dyshormonogenesis (most often as a result of thyroid peroxidase deficiency); pituitary and hypothalamic forms are rare
- L-thyroxine replacement therapy should be initiated within 14 days of life
- screening : determination of thyroid stimulating hormone (TSH) by fluoroimmunoassay (FIA)
- All neonates with confirmed congenital hypothyroidism should undergo electronic screening for congenital hearing loss using transient otoacoustic emissions no later than 3 months after birth
Screening for congenital adrenal hyperplasia[edit | edit source]
thumb|CAH z deficitu 21-hydroxylázy.
- in the Czech Republic it has been carried out since 2006, the incidence of CAH is about 1: 8000 , according to the results of NLS about 1:13 000
- congenital adrenal hyperplasia (CAH) = a congenital disorder of steroid hormone synthesis caused by the absence of one of the five essential enzymes (most commonly 21-hydroxylase deficiency and accumulation of 17alpha-OH-progesterone) resulting in increased production of adrenal androgens → virilization of female external genitalia, premature pseudopuberty ( pseudopubertas praecox ), short stature.
- in 60% of those affected, a defect in mineralocorticoid production is also present
- hydrocortisone replacement therapy (and mineralocorticoids)
- screening : determination of 17alpha-OH-progesterone by immunoassay methods
Screening for cystic fibrosis[edit | edit source]
- in the Czech Republic is carried out from 1 October 2009 , incidence according to NLS 1: 6500
- cystic fibrosis (CF) = AR inherited disease in which mutations in the gene encoding the chloride transporter on the cell membrane occur
- screening:
- examination of the level of immunoreactive trypsinogen (IRT) by immunoassay method
- if CF (high IRT) is suspected, the second step is a molecular genetic analysis of the most common, clearly pathogenic and population-significant mutations in the CFTR gene from the same dry blood droplets on the screening card in which an increased IRT concentration was detected
- with very high IRT and no mutation, the third step is to perform a sweat test using pilocarpine iontophoresis.
Screening for other inherited metabolic disorders (DMP)[edit | edit source]
- screening: tandem mass spectrometry method .
Inherited disorders of amino acid metabolism[edit | edit source]
- Organic aciduria (in NLS since 2009)
náhled|vpravo|Leucinóza (červeně místo poruchy
- leucinosis (maple syrup disease, MSUD) , incidence 1: 185,000 births
- disorder of branched-chain amino acid metabolism (leucine, isoleucine and valine) → accumulation of toxic metabolites
- clinical picture in newborns: food intolerance, failure to thrive, vomiting, lethargy and the smell of urine and earwax after maple syrup or caramel
- without treatment it progresses to irreversible mental retardation, hyperactivity, failure to thrive, seizure disorder, coma, cerebral edema and can lead to death
- glutaric aciduria type I (GA I) , incidence 1: 40,000
- glutaryl-CoA dehydrogenase deficiency, which converts glutaryl-CoA to crotonyl-CoA → increase in the level of toxic glutaric acid and its metabolites
- clinical picture in neonates: macrocephaly but otherwise asymptomatic
- later symptoms: metabolic acidosis, failure to thrive and sudden onset of dystonia and athetosis due to irreversible striatal damage
náhled|vpravo|Izovalerová acidurie (červeně místo poruchy)
- argininemia (ARG) , incidence 1: 300,000 births
- leucine metabolism disorder - isovaleryl-CoA dehydrogenase disorder → specific metabolites that may be toxic accumulate
- clinical picture in neonates: metabolic ketoacidosis, "sweaty feet", dehydration, hyperammonemia, ketonuria, vomiting, hypoglycaemia and failure to thrive; there are also milder forms without manifestations in the neonatal period
- Urea cycle disorders (in NLS since 2016
- argininémie (ARG), , incidence 1: 300,000 births;
- arginase deficiency → accumulation of arginine and ammonia → irritability, eating disorders, vomiting, failure to thrive, neurological symptoms (clumsiness, walking on tiptoe around the age of 2-3 years, delayed psychomotor development, convulsions,…
- hyperammonaemia attacks with increased amino acid breakdown (fever, starvation, infections, surgery) → ammonia is toxic to brain cells in high concentrations → confusion, impaired consciousness, vomiting; life threatening
- type I citrulinaemia (CIT), 2 patients have been diagnosed in the Czech Republic so far
- argininosuccinate synthase deficiency → accumulation of citrulline and ammonia
- severe neonatal form - very rapid progression with high mortality
- late form - manifestations in situations of increased energy demands
- Disorders of sulfur amino acid metabolism (in NLS since 2016
- cystathionine beta-synthase (CBS) deficiency homocystinuria , pyridoxine non-responsive form, incidence 1: 6000 - 1: 20,000
- the most common disorder of sulfur amino acid metabolism, block in homocysteine transsulfurization
- cystathionine beta-synthase deficiency → decreased condensation of homocysteine with serine to cystathionine → homocysteine and its derivatives accumulate
- the enzyme cofactor is pyridoxal-5-phosphate, which is formed from vitamin B6 (pyridoxine) ingested in the diet
- mild deficit: asymptomatic
- severe deficiency: multisystem involvement of eyes, skeleton, central nervous system and blood vessels
- pyridoxine treatment (some patients are non-responsive), a dietary methionine / protein restriction supplement supplemented with a cysteine-enriched preparation of essential amino acids and / or betaine
- homocystinuria from methylenetetrahydrofolate reductase deficiency (MTHFR) , incidence unknown
- diseases of folate and sulfur amino acid metabolism disorders, the most common disorder in homocysteine remethylation
- severe methylenetetrahydrofolate reductase deficiency → 5,10-methylenetetrahydrofolate is not reduced to 5-methyltetrahydrofolate → homocysteine and its derivatives accumulate
- clinical picture of severe deficit: neurological symptoms (psychomotor developmental delay, hypotension and convulsions), later psychiatric problems, neuropathy and thromboembolic events
- treatment: administration of high doses of betaine
Inherited disorders of fatty acid metabolism[edit | edit source]
- Beta-oxidation disorders (in NLS since 2009)
- medium chain fatty acid acyl-CoA dehydrogenase deficiency ( MCAD deficiency ) , incidence 1: 20,000 births
- beta-oxidation disorder of medium-length fatty acids → accumulation of fatty acids and their potentially toxic derivatives
- starvation manifestations and / or periods of increased energy requirements (fever, stress), when energy production is largely dependent on fat metabolism
- clinical picture in newborns: asymptomatic, event. hypoglycemia, metabolic acidosis, hyperammonemia and hepatomegaly, without treatment there is a high mortality, with treatment and prevention of hypoglycemia the prognosis is very good
- long chain fatty acid dehydrogenase 3-hydroxyacyl-CoA deficiency (LCHAD deficiency) , incidence 1: 60,000 births
- clinical picture in neonates: attacks of Reye-like syndrome with cardiomyopathy and / or myopathy (rhabdomyolysis), hepatomegaly, hepatopathy, hypoketotic hypoglycemia, lactic acidosis and failure; even in well-treated patients, the clinical prognosis is uncertain
- very long chain acyl-CoA dehydrogenase deficiency (VLCAD deficiency) , incidence 1: 300,000 births
- clinical picture in neonates with critical deficits: cardiomyopathy, arrhythmias, hepatopathy, rhabdomyolysis and sudden death
- Beta-oxidation transport disorders (in NLS since 2009
- carnitine palmitoyltransferase I (CPT I) deficiency
- beta-oxidation transport of long fatty acids; rare
- clinical picture in neonates: asymptomatic or hypoketotic hypoglycemia, lethargy, hepatomegaly and convulsions, mostly caused by starvation or acute illness
- treatment: a frequent diet (starvation prevention) high in starch-enriched carbohydrates and low in fat
- carnitine palmitoyltransferase II (CPT II) deficiency
- beta-oxidation transport of long fatty acids; incidence unknown
- classic adult form: episodic muscle weakness with myalgia, rhabdomyolysis and myoglobinuria, which are usually provoked by increased exertion, starvation, infection, stress or cold; the infantile form is very rare
- carnitine acyl carnitine translocase (CACT) deficiency
- beta fatty acid transport disorder; rare
Hereditary vitamin conversion disorder[edit | edit source]
- biotinidase deficiency (BTD) - in NLS since 2016
- organic acidemia ; incidence 1: 60,000 births
- clinical picture according to the severity of the deficit: asymptomatic or life-threatening ketoacidosis, or gradual neurological and visual and hearing impairment
Spinal muscular atrophy and severe combined immunodeficiency[edit | edit source]
- pilot project since January 2022, examination is voluntary
- it is performed from a collected dry drop, there is no need to collect more blood
- real-time quantitative polymerase chain reaction (QRTPCR) screening
Newnatal Screening Laboratories[edit | edit source]
Laboratory examination of hereditary metabolic disorders (DPM) by tandem mass spectrometry is performed by:
- General University Hospital, Ke Karlovu 2, 128 08 Prague 2, Department of Hereditary Metabolic Disorders
- Olomouc University Hospital, IPPavlova, 775 20 Olomouc, Laboratory of Inherited Metabolic Disorders, OKBL
Laboratory examination of congenital hypothyroidism (CH) , congenital adrenal hyperplasia (CAH) and cystic fibrosis (CF) using immunoanalytical methods is performed by:
- Královské Vinohrady University Hospital, Šrobárova 50, 100 34 Prague 10, Laboratory of Neonatal Screening, Department of Children and Adolescents
- University Hospital Brno, Černopolní 9, 61300 Brno, workplace Children's Hospital, Department of Clinical Biochemistry and Hematology
Real-time laboratory testing of SMA and SCID by quantitative polymerase chain reaction:
- General University Hospital, Ke Karlovu 2, 128 08 Prague 2, Department of Hereditary Metabolic Disorders
- University Hospital Brno, Černopolní 9, 61300 Brno, Department of Internal Hematology and Oncology, Center for Molecular Biology and Genetics
Notes[edit | edit source]
- until 2009, the Guthrie test (semi-quantitative microbiological test) was used to determine phenylalanine in blood
- a drop of blood is taken on the target of the filter paper
- the filter paper is placed in an agar medium containing bacterial spores (usually Bacillus subtilis) and a competitive growth inhibitor specific for the amino acid sought (for phenylalanine beta-2-thienylalanine)
- incubation,
- evaluation of bacterial growth ( bacteria grow in the presence of phenylalanine in a drop of blood)
- ferric chloride urine test was previously used
LINKS :
https://www-wikiskripta-eu.translate.goog/w/Screening_d%C4%9Bdi%C4%8Dn%C3%BDch_chorob?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=cs ( Screening for hereditary diseases )
https://www-wikiskripta-eu.translate.goog/w/Vrozen%C3%A9_vady_metabolismu_s_akutn%C3%AD_symptomatologi%C3%AD?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=cs ( Congenital defects of metabolism with acute symptomatology )
Reference:
- LEBL, Jan, Kamil PROVAZNÍK and Ludmila HEJCMANOVÁ, et al. Preclinical pediatrics. 2nd edition. Prague: Galén, 2007. pp. 183. ISBN 978-80-7262-438-6
- LEBL, Jan, Kamil PROVAZNÍK and Ludmila HEJCMANOVÁ, et al. Preclinical pediatrics. 2nd edition. Prague: Galén, 2007. pp. 184. ISBN 978-80-7262-438-6 .\
- JURÁSKOVÁ, Dana. Bulletin of the Ministry of Health of the Czech Republic 6/2009 [online]. © 2009. Last revision 2009, [cited. 11. 12. 2009]. < https://udmp.lf1.cuni.cz/ns/ns_files/6_2009.pdf >.
- http://www.novorozeneckyscreening.cz/vysledky-ns-2012-19-10-2015-131436
- LEBL, Jan, Kamil PROVAZNÍK and Ludmila HEJCMANOVÁ, et al. Preclinical pediatrics. 2nd edition. Prague: Galén, 2007. pp. 185. ISBN 978-80-7262-438-6 .
- COLLECTIVE WWW.NOVOROZENECKYSCREENING.CZ ,. What is neonatal screening [online]. [feeling. 2017-03-11]. < http://www.novorozeneckyscreening.cz/ov-co-je-novorozenecky-screening >.
- Czech Republic. Bulletin of the Ministry of Health of the Czech Republic 14/2021. 2021. Also available from URL < https://www.mzcr.cz/wp-content/uploads/2021/12/Vestnik-MZ_14-2021.pdf >.
- VÁVROVÁ, Jaroslava. Nomenclature of the Ministry of Health of the Czech Republic [online]. © 2008. Last revision 2008, [cited. 11. 12. 2009]. < http://ciselniky.dasta.mzcr.cz/hypertext/200640/hypertext/JVADB.htm >.
- ↑ LEBL, Jan – PROVAZNÍK, Kamil – HEJCMANOVÁ, Ludmila, et al. Preklinická pediatrie. 2. edition. Praha : Galén, 2007. pp. 184. ISBN 978-80-7262-438-6.
- ↑ http://www.novorozeneckyscreening.cz/vysledky-ns-2012-19-10-2015-131436